Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB41 + SCTB39-1 with or without standard therapy in advanced malignant solid tumors
CTR20261827Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- May 2026
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB41, SCTB39G in Nonhematologic neoplasms, sponsored by Sinocelltech Group Limited. Started May 2026; status: active.
02
Drugs
SCTB41SCTB39G
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20261827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261827.